ArticleCancer medicine2025
ZC3H12D and DDX5 Antagonistically Regulate Cyclin D1 mRNA Stability and Cell Cycle Progression in Breast Cancer.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Regnase pathway: a core axis in immune regulation and inflammatory disease.Frontiers in immunology · 2026Review
- ZC3H12D and DDX5 Antagonistically Regulate Cyclin D1 mRNA Stability and Cell Cycle Progression in Breast Cancer.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAn imbalance between the expression of cell cycle-promoting and cell cycle-inhibiting genes triggers uncontrolled cell cycle progression in cancer cells. However, the mechanism controlling the expression of cell cycle-related genes, especially those whose expression is mediated by RNA-binding proteins (RBPs), remains elusive.
methodsAll RBP expression in human breast cancer was analyzed by bioinformatic methods. The expression and prognostic value of RBPs ZC3H12D (zinc finger CCCH domain-containing protein 12D) and DDX5 (DEAD box protein 5) in breast cancer were analyzed in public databases and tumor samples. The functions of ZC3H12D and DDX5 in breast tumor cell cycle regulation and tumor progression were determined in vitro and in vivo. RNA sequencing, infrared crosslinking immunoprecipitation and RNA sequencing (irCLIP-Seq), RNA immunoprecipitation (RIP), luciferase assay, mRNA stability detection, protein pull-down, RNA pull-down, mass spectrometry, immunocytochemistry, RNA-EMSA, and RNA immunoprecipitation chromatin immunoprecipitation (RIP-ChIP) were conducted to determine the underlying molecular mechanisms of ZC3H12D and DDX5.
resultsThe expression of ZC3H12D and DDX5 was reduced and increased in human breast cancer tissues, respectively, and was closely related to the prognosis of breast cancer patients. ZC3H12D and DDX5 could inhibit or promote breast tumor progression by reciprocally controlling the G1/S transition of tumor cells. Mechanistically, ZC3H12D destabilized the CCND1 mRNA by directly binding the conserved stem-loop structure localized in the 3'-untranslated region (3'UTR) via the RNase domain. Ribosomal protein L4 (RPL4) was critical for ZC3H12D-mediated mRNA degradation. Besides, DDX5 was shown to bind the common RNA stem-loop structure of CCND1 but increased its stability.
conclusionsZC3H12D and DDX5 are a pair of cell cycle antagonists in breast cancer that inhibit or promote the cell cycle progression by modulating the expression of cell cycle-promoting genes, which provide new insights into the prevention of uncontrolled cancer cell cycle transitions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.